Cargando…

Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas

INTRODUCTION: The panel of markers used for molecular classification include estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor (HER)-2/neu, p53, Bcl-2 and basal markers like cytokeratin 5/6 or epidermal growth factor receptor (EGFR). Among these, EGFR plays...

Descripción completa

Detalles Bibliográficos
Autores principales:	Changavi, Arathi A, Shashikala, Arundhathi, Ramji, Ashwini S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559633/ https://www.ncbi.nlm.nih.gov/pubmed/26417156 http://dx.doi.org/10.4103/0974-2727.163129

Ejemplares similares

Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer
por: Ma, Mingming, et al.
Publicado: (2021)

Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
por: Kim, Aeri, et al.
Publicado: (2017)

Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome
por: Munawar, Shahzeb, et al.
Publicado: (2021)

Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker
por: de Araújo, Rogério Agenor, et al.
Publicado: (2022)

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
por: You, Kyu Sic, et al.
Publicado: (2021)

Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
por: Cao, Wen-Ming, et al.
Publicado: (2015)

Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas.
por: Cattoretti, G., et al.
Publicado: (1988)

Fibrinogen/Albumin Ratio (FAR) in Patients with Triple Negative Breast Cancer and Its Relationship with Epidermal Growth Factor Receptor Expression
por: Gao, Wenbo, et al.
Publicado: (2021)

Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype
por: Nisticò, Nancy, et al.
Publicado: (2023)

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
por: Teng, Yvonne Hui-Fang, et al.
Publicado: (2011)

Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
por: Mlole, Angela T, et al.
Publicado: (2020)

Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor
por: Liu, Yan, et al.
Publicado: (2020)

Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort
por: Zakaria, Zubaidah, et al.
Publicado: (2019)

Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
por: Toyama, Tatsuya, et al.
Publicado: (2008)

Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation
por: Wischmann, Franz-Josef, et al.
Publicado: (2023)

Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression
por: Hessel, Harald, et al.
Publicado: (2018)

Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan
por: Ali, Seemal, et al.
Publicado: (2022)

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
por: Roberts, Melyssa S., et al.
Publicado: (2020)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine
por: Zhu, Yiping, et al.
Publicado: (2021)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Methylation profile of triple-negative breast carcinomas
por: Branham, M T, et al.
Publicado: (2012)

Factors That Predict Biological Aggressiveness in Estrogen Receptor–Positive / Human Epidermal Growth Factor Receptor 2–Negative / Lymph Node–Negative Breast Cancer
por: Arthur, Lauren E., et al.
Publicado: (2020)

Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
por: Asano, Yuka, et al.
Publicado: (2017)

Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells
por: Oh, Sunhwa, et al.
Publicado: (2017)

Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma
por: Jin, Linfang, et al.
Publicado: (2020)

Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met
por: Mueller, Kelly L, et al.
Publicado: (2012)

Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells
por: Kashyap, Akanksha, et al.
Publicado: (2021)

Fibroblast growth factor receptor 4 as a prognostic indicator in triple-negative breast cancer
por: Wei, Wei, et al.
Publicado: (2020)

Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability
por: Powell, Catherine A., et al.
Publicado: (2015)

bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.
por: Leek, R. D., et al.
Publicado: (1994)

Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas
por: Kuo, Wen-Hung, et al.
Publicado: (2012)

Targeted therapy of triple negative MDA-MB-468 breast cancer with curcumin delivered by epidermal growth factor-conjugated phospholipid nanoparticles
por: Jung, Kyung-Ho, et al.
Publicado: (2018)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

p16 expression correlates with basal-like triple-negative breast carcinoma
por: Abou-Bakr, Amany A, et al.
Publicado: (2013)

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer
por: Tomiguchi, Mai, et al.
Publicado: (2016)

Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells
por: Yi, Yong Weon, et al.
Publicado: (2022)

Triple negative breast carcinoma is a prognostic factor in Taiwanese women
por: Lin, Che, et al.
Publicado: (2009)

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
por: Zhang, Jiaqiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tim2n6s9k20ka2d3bb6lptanra